[ad_1]
The Ministry of Health today announced (3) the incorporation of sapropterin dihydrochloride, a drug used in the treatment of phenylketonuria, into the Unified Health System (UAS). The remedy must be available on the public network within 180 days and will be offered to women in pre-conception or during the gestation period and who have obtained a positive result to the drug.
According to the record, the use Sapropterin dihydrochloride for the treatment of phenylketonuria is complementary to the diet, with restriction of foods such as meat, eggs, wheat and beans, in addition to the Use of metabolic preparations rich in amino acids, vitamins and minerals
"To incorporate the drug into the SUS, discussions were held with health professionals and specialists who make up the National Commission for Health. incorporation of new technologies to SUS (Conitec), "said the ministry in a note. "In addition, the observations and suggestions of the population were also taken into account, with the majority of patients and relatives of patients."
Phenylketonuria has a genetic heritage and causes the birth of an individual without a significant enzyme (phenylalanine), preventing the body from working well to break down the amino acid molecules present in animal and plant proteins (phenylalanine- FAL). The high levels of this amino acid and its badociated substances in the body exert a toxic action on various organs, especially the brain.
Figures
Data from the Brazilian Society of Pediatrics reveal that one in 12,000 live births is diagnosed. with phenylketonuria. The disease is identified from the birth of the child by the foot test. The review identifies five other diseases: conbad hypothyroidism, sickle cell disease and other hemoglobinopathies, cystic fibrosis, conbad adrenal hyperplasia and biotinidase deficiency.
[ad_2]
Source link
